FDA grants accelerated approval for first engineered T cell therapy to treat adults with synovial sarcoma

The U.S. Food and Drug Administration (FDA) has granted accelerated approval for the immunotherapy afamitresgene autoleuecel (Tecelra®, also known as afami-cel) for the treatment of adults with a rare soft tissue cancer called synovial sarcoma.

FDA-ordered report tackles how to manage cybersecurity risks of legacy devices

Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: A report commissioned by the

November 16, 2023

UniQure stock doubles on FDA ‘alignment’ over accelerated approval for Huntington’s drug

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

December 11, 2024

Regular GP visits could help reduce workload in practices and hospitals

New research indicates that regularly seeing the same GP could reduce workload in practices and hospitals, potentially freeing up appointments for patients.

January 28, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.